In the title pymiridine-2,4-dione derivative, C 14 H 16 N 2 O 2 S, the dihedral angle between the six-membered rings is 66.69 (10) . The molecule is twisted about the C p -S (p = pyrimidine) bond, with a C-S-C-N torsion angle of À19.57 (16) . In the crystal, adjacent molecules form inversion dimers through pairs of strong N-HÁ Á ÁO hydrogen bonds, generating an R 2 2 (8) ring motif. The dimers are connected into chains extending along the c-axis direction through additional N-HÁ Á ÁO hydrogen bonds.
Related literature
For the pharmacological activity of pyrimidine-2,4-dione derivatives, see: Al-Abdullah et al. (2011); El-Emam et al. (2004) ; Hopkins et al. (1996) ; Klein et al. (2001) ; Miyasaka et al. (1989) ; Nencka et al. (2006) ; Russ et al. (2003) ; Tanaka et al. (1995) ; For related pyrimidine-2,4-dione structures, see: El-Brollosy et al. (2009) ; Wang et al. (2006) . For hydrogen-bond motifs, see: Bernstein et al. (1995) . For reference bond lengths, see: Allen et al. (1987) Table 1 Hydrogen-bond geometry (Å , ).
Symmetry codes: (i) Àx þ 1; Ày; Àz þ 1; (ii) x; Ày þ 1 2 ; z þ 1 2 .
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008) ; program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 Pyrimidine-2,4-diones and their related derivatives have long been known for their diverse chemotherapeutic activities including antiviral activity against the HIV (Miyasaka et al., 1989; Tanaka et al., 1995; Hopkins et al., 1996; El-Emam et al., 2004) , and HSV viruses (Russ et al., 2003) . In addition, potent anticancer activity was observed for several pyrimidine-2,4-diones (Klein et al., 2001; Nencka et al., 2006) . In continuation to our interest in the chemical and pharmacological properties of pyrimidine and uracil derivatives (Al-Abdullah et al., 2011; El-Brollosy et al., 2009) , we have synthesized the title compound (I) as a potential chemotherapeutic agent.
The title compound (I) is a derivative of pymiridine-2,4-dione. The heterocycle contains the structural unit CON 2 H 2 CO, forming the dihedral angle of 66.69 (10)° with the adjacent benzene ring. The molecule is bent ( Fig. 1 ) at the S atom with a C-S-C-N torsion angle of -19.57 (16)°. The bond lengths (Allen et al., 1987) and angles in the title compound are within normal ranges and are comparable with those reported earlier (El-Brollosy et al., 2009; Wang et al., 2006) . The crystal structure features for two types of intermolecular N-H···O hydrogen bonds (Table 1) . Two adjacent molecules form inversion-related dimers through strong N2-H2A···O1 hydrogen bonds (symmetry code: -x + 1, -y, -z + 1), generating an R 2 2 (8) ring motif (Bernstein et al., 1995) (Fig. 2) . These dimers are further connected into chains extending along c axis through additional N1-H1N1···O2 hydrogen bonds (symmetry code: x, -y +1/2, z + 1/2) ( Fig. 2) . Crystal stability is mainly consolidated by these hydrogen bonding interactions forming two-dimensional networks parallel to the bc plane.
Experimental
A mixture of 6-chloro-5-propyluracil (943 mg, 0.005 mol), p-thiocresol (621 mg, 0.005 mol) and potassium hydroxide (281 mg, 0.005 mol), in ethanol (10 ml), was heated under reflux for 3 h. The solvent was then distilled off in vacuo and the residue was washed with cold water, dried and crystallized from ethanol to yield 995 mg (72%) of the title compound 
Refinement
The nitrogen-bound H-atoms were located in a difference Fourier map and were refined freely. Other H atoms were positioned geometrically (C=H 0.93-0.97 Å) and refined using a riding model with U iso (H) = 1.2 U eq (C) or 1.5 U eq (C) for supplementary materials sup-2 Acta Cryst. (2014). E70, o179-o180 methyl H atoms. A rotating group model was used for the methyl group.
Computing details
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT (Bruker, 2009); program(s) used to solve structure: SHELXTL (Sheldrick, 2008) ; program(s) used to refine structure: SHELXTL (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication:
SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009 ).
Figure 1
The molecular structure of the title compound with the atom labelling scheme and 30% probability displacement ellipsoids.
Figure 2
Crystal packing of the title compound, viewed along the b axis, showing the N1-H1N1···O2 and N2-H2N2···O1 intermolecular hydrogen bonds as dashed lines. H-atoms not involved in the hydrogen bonding are omited for clarity. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
5-Propyl-6-(p-tolylsulfanyl)pyrimidine-2,4(1H,3H)-dione

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.28497 (6) 0.53022 ( 0.0977 (10) 0.0498 (7) 0.0494 (7) 0.0248 (7) 0.0507 (7) 0.0134 (6) N1 0.0588 (8) 0.0447 (8) 0.0356 (7) 0.0101 (6) 0.0303 (6) 0.0027 (6) C1 0.0483 (8) 0.0411 (9) 0.0399 (8) 0.0035 (7) 0.0231 (7) 0.0013 (7) O2 0.0888 (9) 0.0579 (8) 0.0487 (7) 0.0058 (7) 0.0494 (7) 0.0040 (6) N2 0.0609 (8) 0.0421 (8) 0.0392 (7) 0.0091 (6) 0.0323 (7) 0.0029 (6) C2 0.0523 (8) 0.0434 (9) 0.0335 (7) 0.0081 (7) 0.0243 (7) 0.0018 (7) C3 0.0545 (9) 0.0461 (9) 0.0367 (8) −0.0002 (7) 0.0271 (7) 0.0009 (7) C4 0.0560 (9) 0.0443 (9) 0.0414 (8) 0.0019 (7) 0.0270 (7) 0.0026 (7) 
